Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirasemtiv in ALS
NCT02496767Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Sep 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of tirasemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Started Sep 2015; status: completed.
02
Drugs
tirasemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02496767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496767.